Miniatura

Fitxers

1-s2.0-S0163445325001616-main.pdf (4.84 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-08-05

Llicència de publicació

cc by-nc-nd (c) González Sánchez, Alejandra et al, 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/223149

Evolutionary dynamics of HRSV following the implementation of nirsevimab immunoprophylaxis in Catalonia (2023-2024)

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.jinf.2025.106567

Resum

Objectives: To evaluate the effect of the selective pressure exerted by nirsevimab on human respiratory syncytial virus (HRSV) in Catalonia (2023-2024) by analysing viral mutations, diversity, and evolutionary dynamics, based on viruses characterised from non-immunised and previously immunised patients. Methods: Respiratory samples were collected through the SIVIC sentinel network and three hospitals in Catalonia. HRSV-positive samples underwent whole-genome sequencing (WGS), or F gene sequencing when WGS was not feasible. Viral diversity, phylogenetics, and selection pressure were assessed. Results: A total of 251 WGS (HRSV-A: 165; HRSV-B: 86) and 27 F gene sequences (HRSV-A: 13; HRSV-B: 14) were obtained for the non-immunised group. For immunised cases, 79 WGS (HRSV-A: 67; HRSV-B: 12) and 12 F sequences (HRSV-A: 10; HRSV-B: 2) were analysed. Lineage distribution remained similar between groups. Nucleotide diversity was similar for HRSV-A groups, though reduced in immunised HRSV-B. Selection pressure analyses suggested a shift toward neutral evolution in immunised samples. Mutations N63S, K65R, I206T , K209E (HRSV-A) , K68E, R209Q, and S211N (HRSV-B) were detected in nirse- vimab epitope, with K209E and K68E absent in non-immunised samples. Conclusions: Nirsevimab immunisation may influence HRSV evolution, particularly in HRSV-B. Continued genomic surveillance is crucial for early mAb-resistant mutants detection. (c) 2025 Published by Elsevier Ltd on behalf of The British Infection Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Matèries

Immunoteràpia, Epidemiologia molecular

Matèries (anglès)

Immunotheraphy, Molecular epidemiology

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

GONZÁLEZ SÁNCHEZ, Alejandra, ANDRÉS LACUEVA, Ma. cristina, PRATS MÉNDEZ, Ignasi, PIÑANA, Maria, COMA, Ermengol, BERNET SÁNCHEZ, Albert, CASAÑ LOPEZ, Cristina, TORRALBA CALERO, Miguel, GUTIÉRREZ, Cristina, RECIO COMÍ, Gemma, CALATAYUD, Laura, SAUBÍ, Narcís, CREUS COSTA, Anna, VILA, Jorgina, ARNEDO MUÑOZ, Maria, RANDO, Ariadna, NADAL BARÓN, Patricia, ESPERALBA, Juliana, BALADA, Eva, SORIANO ARANDES, Antoni, AYATS, Josefina, MENDIOROZ, Jacobo, GONZÁLEZ LÓPEZ, Juan josé, LARROSA, Nieves, PUMAROLA, Tomàs, MARTÍNEZ URTAZA, Jaime, ANTÓN, Andrés. Evolutionary dynamics of HRSV following the implementation of nirsevimab immunoprophylaxis in Catalonia (2023-2024). _Journal of Infection_. 2025. Vol. 91, núm. 3. [consulta: 24 de gener de 2026]. ISSN: 0163-4453. [Disponible a: https://hdl.handle.net/2445/223149]

Exportar metadades

JSON - METS

Compartir registre